Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Pfizer Announces Retirement of Chief Financial Officer Frank D’Ameliohttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio


Pfizer Inc. (NYSE: PFE) today announced that Frank D’Amelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply at Pfizer after a nearly 15 year

Pfizer Announces Retirement of Chief Financial Officer Frank D’Ameliohttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio


Pfizer Inc. (NYSE: PFE) today announced that Frank D’Amelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply at Pfizer after a nearly 15 year

GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment


GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative

Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidatehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate


Pfizer Inc. today announced it is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, PAXLOVID™ (PF-07321332; ritonavir), for the treatment of mild to

Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidatehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate


Pfizer Inc. today announced it is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, PAXLOVID™ (PF-07321332; ritonavir), for the treatment of mild to

New Report Finds Value-Based Care Agreements Benefited Humana Medicare Advantage Members with Reduced Hospitalizations, More Preventive Care During COVID-19 Pandemic: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
New Report Finds Value-Based Care Agreements Benefited Humana Medicare Advantage Members with Reduced Hospitalizations, More Preventive Care During COVID-19 Pandemic


Humana Inc. (NYSE: HUM) published its eighth annual Value-based Care (VBC) Report today, showing that Humana individual Medicare Advantage (MA) beneficiaries receiving care from primary care

Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services division

Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countrieshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries


Pfizer Inc. (NYSE: PFE) and the Medicines Patent Pool (MPP), a United Nations-backed public health organization working to increase access to life-saving medicines for low- and middle-income

Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countrieshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries


Pfizer Inc. (NYSE: PFE) and the Medicines Patent Pool (MPP), a United Nations-backed public health organization working to increase access to life-saving medicines for low- and middle-income

Pulse Biosciences Reports Third Quarter 2021 Financial Results: https://mms.businesswire.com/media/20211005005394/en/913083/5/pulse-logo.jpg
Pulse Biosciences Reports Third Quarter 2021 Financial Results


Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial

PINC AI™ Applied Sciences (PAS) and Mölnlycke Health Care AB Clinical Trial Aims to Reduce Hospital-Acquired Infections (HAIs): https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
PINC AI™ Applied Sciences (PAS) and Mölnlycke Health Care AB Clinical Trial Aims to Reduce Hospital-Acquired Infections (HAIs)


The PINC AI™ Applied Sciences (PAS) team, a division of PINC AI, the technology and services platform of Premier, Inc. (NASDAQ: PINC), and Mölnlycke, a world-leading medical solutions company

Savara to Participate in Two Upcoming Investor Healthcare Conferences: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara to Participate in Two Upcoming Investor Healthcare Conferences


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the following healthcare

Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting


Novocure (NASDAQ: NVCR) today announced 31 presentations on Tumor Treating Fields (TTFields) will be featured at the Society for Neuro-Oncology (SNO) 2021 Annual Meeting from Nov. 18 to Nov. 21 in

2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma


Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Oncology at the McKnight Brain Institute at the University of Florida, has released updated data from the

Pfizer Aktie: Impfung jetzt überflüssig?
Pfizer Aktie: Impfung jetzt überflüssig?
Die Wunderpille treibt die Pfizer Aktie auf ein neues 5-Jahreshoch. Doch was steckt genau hinter dem Medikament?
Pfizer Aktie: Impfung jetzt überflüssig?
Pfizer Aktie: Impfung jetzt überflüssig?
Die Wunderpille treibt die Pfizer Aktie auf ein neues 5-Jahreshoch. Doch was steckt genau hinter dem Medikament?
LivaNova Comments on Decision by Court of Appeal of Milan: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova Comments on Decision by Court of Appeal of Milan


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, commented on the decision delivered today by the Court of Appeal of Milan (CoA) for LivaNova to pay damages

Savara Reports Third Quarter 2021 Financial Results and Provides Business Update: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara Reports Third Quarter 2021 Financial Results and Provides Business Update


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the third quarter ending September 30, 2021 and

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported

GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

Humana Earns Designation as #1 Large Company Military Friendly Employer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Earns Designation as #1 Large Company Military Friendly Employer


Humana Inc. (NYSE: HUM) announced today that it has been named the #1 Military Friendly Employer in the nation in the large company category by Viqtory Media for the second year in a row.



“Humana

Eastlake Behavioral Health Hospital Approved by Chula Vista Planning Commission: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Eastlake Behavioral Health Hospital Approved by Chula Vista Planning Commission


The Chula Vista Planning Commission today approved a new inpatient behavioral health hospital in the Eastlake community of Chula Vista. The Eastlake behavioral health hospital will be operated by a

ICON Announces the Expansion of its Accellacare Site Network: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON Announces the Expansion of its Accellacare Site Network


ICON plc, (NASDAQ: ICLR) a global provider of drug development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, today announced that